People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sonoma Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $265.0M | $7.7B | 2021 |
| Rheos Medicines, Inc. | — | Biotechnology | Series B | $27.5M | $1.1B | 2018 |
Jeffrey Bluestone at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Bluestone on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Klausner | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| Terry Rosen | 1 | 4 |
| Fan Yu | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Stephen Sherwin | 1 | 2 |
| Sanjay Keswani | 1 | 2 |
| Maggie Wilderotter | 1 | 2 |
| Dan Matloff | 1 | 2 |
| Gad Soffer | 1 | 1 |
| Ryan Cohlhepp | 1 | 1 |
| J. Duncan Higgons | 1 | 1 |
| Toni Hoover | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.